What Do Core Biopsy Results Mean in Invasive Ductal Cancer?

A core needle biopsy provides critical initial information to formally diagnose invasive ductal carcinoma. It tells your care team the specific type of cancer, estimates its behavior, and identifies the biomarkers that might fuel it. However, reading a new cancer pathology report can feel overwhelming, and it helps to remember that the report is only one part of the treatment-planning process. Sometimes, the tissue sample is too small, damaged, or doesn’t match your imaging, meaning you might need another biopsy or a surgical excision to get a complete picture.

What the Pathology Report Shows

When the pathologist examines the tissue from your core needle biopsy, they look for several key pieces of information to guide your care:

• Invasive Carcinoma and Histologic Type: The biopsy confirms whether cancer cells have broken out of the milk ducts and invaded surrounding breast tissue. While invasive ductal carcinoma—now commonly called invasive carcinoma of no special type—is the most common, pathologists also check the tissue’s appearance to rule out other specific subtypes ^[1].
• Tumor Grade (Nottingham Grade): This grade (usually reported as 1, 2, or 3) helps predict the tumor’s behavior. It is based on three features: how closely the cells resemble normal tissue (tubule formation), how abnormal the cells look (pleomorphism), and how many cells are actively dividing (mitotic activity). Note that the grade on a core biopsy may occasionally differ from the final surgical specimen because the needle only samples a portion of the tumor.
• Hormone Receptors (ER and PR): Pathologists check if the cancer cells have receptors for estrogen (ER) and progesterone (PR). The report typically lists the percentage of cells that stain positive. Core biopsy samples are generally reliable for this testing ^[2]. A positive result predicts that you will likely benefit from hormone-blocking therapies ^[3].
• HER2 Status: HER2 is a protein that can fuel cancer growth and is assessed using internationally standardized criteria ^[4]. Results are usually given as a score from 0 to 3+. A score of 0 or 1+ is negative, while 3+ is positive. If the result is 2+ (equivocal), additional confirmatory testing (such as in-situ hybridization, or ISH) is performed to get a clear answer ^[5].
• Ki-67: This marker estimates the percentage of cancer cells that are actively dividing. It provides an additional clue about the tumor’s growth rate. However, it is not routinely required for every patient, and measuring it uniformly can be challenging for laboratories ^[6]. It is used as a supplementary piece of information rather than a standalone deciding factor.

What Your Biopsy Cannot Tell You

While a core biopsy is essential, it does not provide the full picture needed to finalize your treatment plan. The biopsy generally cannot tell you:

• The Clinical Stage: Stage depends on the complete size of the tumor and whether the cancer has spread to lymph nodes or other organs.
• Lymph Node Status: A standard breast core biopsy does not evaluate your lymph nodes.
• Surgical Margins: Only surgery can confirm if a rim of healthy tissue completely surrounds the removed tumor.

Your complete treatment plan will depend on a combination of the biopsy, imaging, physical examination, your personal health preferences, and eventually surgery or lymph node assessment.

When Is Another Biopsy or Surgery Needed?

Even after a successful core needle biopsy, your care team may recommend a repeat biopsy or additional surgery. This is a normal part of the diagnostic process and typically happens for three main reasons:

1. The Biopsy Doesn’t Match the Imaging

After your biopsy, your breast-care team compares the laboratory results with your mammogram, ultrasound, or MRI to ensure the pathology explains the imaging findings ^[7]. If the results do not adequately explain the imaging abnormality, this is called a discordant result. When findings are discordant, further diagnostic work-up—such as a repeat image-guided biopsy or surgical biopsy—is needed to make sure cancer wasn’t missed ^[8].

2. The Sample is Inadequate or Damaged

Sometimes the biopsy needle retrieves too little tissue, or the tissue is crushed (crush artifact) or contains dead cells (necrosis). When the sample is scant or damaged, the pathologist may not be able to confidently classify the cancer type or run the necessary biomarker tests. In these cases, more tissue is required. Additionally, if an initial core biopsy tests negative for HER2 but the sample was limited or discordant with other features, doctors may recommend selectively retesting the larger tumor removed during surgery ^[9].

3. Atypical or High-Risk Lesions

Sometimes a biopsy is performed and primarily shows high-risk, non-invasive abnormalities—such as atypical ductal hyperplasia (ADH)—without any invasive cancer. In these specific cases, a surgical biopsy is usually recommended ^[10]. This is because the needle may have only captured the edge of a more serious area, and surgery is needed to check for invasive disease nearby. (If your core biopsy has already confirmed invasive cancer, your surgical plan will be driven by the invasive cancer itself, rather than incidental high-risk lesions).